Dear Kidney Transplant Recipient,
Anti-rejection medication is necessary to prevent rejection, and keep a kidney transplant functioning. However, different transplant centres use different combination of anti-rejection medications.
We would like to undertake research looking at these different types of medications used. We do not plan an intervention study – we wish to use data that is already available to inform practice. We wish to look at why clinicians use the type of anti-rejection medication they prescribe, and also to understand the patient’s view of practices and side effects.
The overall aim of the research is to provide evidence for clinicians and patients on the benefit of an individual approach to immunosuppression. Not all kidney transplant recipients have equal risk of rejection, and similarly, side effects of medications differ amongst patients.
Anti-rejection prescriptions vary across the London Transplant Centres, and we initially would like to bring in patients from different backgrounds (e.g. age, ethnicity, gender) from each centre to form a patient steering group to inform the research.
We would first like to hold a webinar to provide some background information to the work. Following this, we would like to offer a focus group or individual meetings to get more detailed thoughts and feedback. The focus groups and individual meetings will be reimbursed.
If you are interested in getting involved or just hearing about immunosuppression, please sign up for our webinar on 25th November at 17.00. If you are unable to attend, we will be able to send you the recording afterwards.
Many thanks,
Michelle Willicombe
(Transplant doctor and researcher at Imperial College Renal and Transplant Centre)
Registration for webinar: https://forms.office.com/e/vjwBB9Qym6